Core Insights - Enlivex Therapeutics Ltd. has completed the dosing and initial follow-up for the first patient in its Phase I clinical trial of Allocetra™ for psoriatic arthritis, with no safety concerns reported [1] - The trial aims to recruit six patients who have not adequately responded to conventional therapies, focusing on safety and disease activity parameters over 12 months [2] - The CEO highlighted the potential market opportunity for Allocetra™ in treating psoriatic arthritis, a condition with limited treatment options [3] Company Overview - Enlivex is a clinical-stage company developing Allocetra™, a macrophage reprogramming immunotherapy designed to restore macrophages to their homeostatic state, which is essential for immune system balance [4] Industry Insights - The global market for psoriatic arthritis treatments was valued at approximately 20.5 billion by 2032, with a CAGR of 7.4% from 2024 to 2032 [3] - Alternative projections suggest the market could increase from 24.87 billion by 2031, representing a CAGR of 12.1% from 2024 to 2031 [3] - The current treatment landscape for psoriatic arthritis faces challenges such as limited efficacy, side effects, high costs, and underdiagnosis, necessitating ongoing research for better treatment options [3]
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis